Prophylactic Administration of CN-105 Confers Neuroprotection Against Acute Brain Injury
Abstract
We have previously established that the pentapeptide CN-105 (Ac-VSRRR-COOH ) improves functional and outcome and reduces histological injury in a murine model of traumatic brain injury (closed head injury caused by fluid percussion against the intact skull). The major goal of this project is to establish whether this neuroprotective pentapeptide would be effective in mitigating secondary neuronal injury and improving functional outcomes when administered prior to closed head injury, as this would be a potentially viable strategy to reduce morbidity of traumatic brain injury associated with combat. As described in the statement of work, during the initial year of this proposal, we have tested the efficacy of CN-105 when administered prophylactically in both a moderate single head injury, and paradigm of milder head injuries occurring on a weekly basis over 5 weeks. In addition, we performed the initial work comparing the bioavailability and pharmacokinetics between intravenous, intraperitoneal, intranasal, and oral modes of administration.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2017
- Accession Number
- AD1046254
Entities
People
- Daniel Laskowitz
Organizations
- Duke University